Navigation Links
Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Date:4/30/2008

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that it has appointed Eliot M. Lurier, CPA, as its Chief Financial Officer.

Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, Inc., commented on the appointment, "Eliot is an innovative and experienced senior financial executive with an entrepreneurial spirit and a proven record of achievement in managing growth for publicly traded companies. The addition of Eliot to the senior management team provides financial management and operational skills that we need to develop and grow our business."

Mr. Lurier, age 50, has more than 25 years of financial management experience, primarily in the life sciences industry. Prior to joining Interleukin Genetics, he was Vice President, Finance and Administration and Chief Financial Officer of Nucryst Pharmaceuticals (Nasdaq: NCST, TSX: NCS), where he successfully completed a $45 million IPO within 6 months of joining the company and was responsible for SEC reporting and the implementation of Sarbanes-Oxley requirements. Previously, he served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals, Inc., where he established all policies for managing business operations.

Mr. Lurier commented, "I am very excited about the opportunity to join Interleukin Genetics. The Company is well positioned to become a leading provider of preventive consumer products and genetic tests for sale to the emerging personalized health market. I look forward to helping the Company communicate the value of such tests to the investment community."

Prior to joining Bridge Pharmaceuticals, Inc., Mr. Lurier held a number of senior-level financial positions including Chief Financial Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer and Vice President of Finance of Ascent Pediatrics, Inc., a publicly traded pharmaceutical company.

Earlier in his career, Mr. Lurier was Senior Accountant at Coopers and Lybrand. He earned a B.S. in Accounting from Syracuse University and is a Certified Public Accountant in Massachusetts.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
2. Interleukin Genetics Retains Top Life Science Communications Firms
3. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
6. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
7. Interleukin Genetics Announces Management and Board Appointments
8. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
9. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
10. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
11. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
(Date:3/23/2017)... ... 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event ... companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in ... popularity is due to its new team building format, a way for teams to not ...
(Date:3/23/2017)... LOUISVILLE, Colo. , March 23, 2017  GlobeImmune, ... purchase agreement for the sale of 12,835,490 shares of ... the  NantWorks  ecosystem of companies. In connection with the sale ... GlobeImmune $100,000 in cash and issue to GlobeImmune 200,000 ... common stock. "We are pleased to ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
Breaking Biology News(10 mins):